PKM and esophageal squamous cell carcinoma: At the fundamental metabolic level of esophageal squamous cell carcinoma, ESRRG inhibits the transcriptional expression of PKM2 by directly binding to its promoter, thereby reducing glycolytic activity and blocking cell proliferation.